Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy
Cells · 05.08.2026 · 15 (15) · 1422
DOI: 10.3390/cells15151422 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 05.08.2026. Verfasst von Jianing Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Metabolic reprogramming constitutes a fundamental hallmark of malignancy, orchestrating a hostile tumor microenvironment (TME) that severely compromises anti-tumor immunity. Despite the transformative success of immune checkpoint blockade and adoptive cell therapies, clinical efficacy is frequently curtailed by the metabolic barriers imposed by the TME. This review systematically elucidates the complex metabolic interplay between tumor cells and infiltrating T cells, highlighting two defining mechanisms driving immune evasion: the competitive sequestration of essential nutrients and the accumulation of immunosuppressive oncometabolites. We detail how the depletion of glucose and critical amino acids (glutamine, arginine, methionine, etc.) imposes a state of “metabolic siege” on T cells, impairing their bioenergetics and effector functions. Concurrently, we explore how accumulated metabolites—such as lactate, succinate, 2-hydroxyglutarate, kynurenine, and lipids—function as non-canonical signaling molecules to subvert immune surveillance via epigenetic remodeling and oxidative stress. Furthermore, we synthesize emerging therapeutic strategies designed to dismantle this metabolic barrier, including targeting metabolic enzymes (IDO1 and FASN) and transporters, repurposing metabolic waste, and genetically engineering T cells with enhanced metabolic fitness and resilience. By integrating the latest insights into the “metabolism–epigenetics–immunity” axis, this review provides a theoretical foundation for developing next-generation immunotherapies that target metabolic vulnerabilities to overcome resistance in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, China.
- Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Zhang, J., Tang, Z., Wang, Y., Wan, J., Zhou, Y., Li, J., & Ming, J. (2026). Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy. Cells, 15(15), 1422. https://doi.org/10.3390/cells15151422
Vancouver
Zhang J, Tang Z, Wang Y, Wan J, Zhou Y, Li J, et al. Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy. Cells. 2026;15(15):1422. doi:10.3390/cells15151422
BibTeX
@article{Zhang2026,
author = {Zhang, Jianing and Tang, Zimei and Wang, Yiran and Wan, Jiaying and Zhou, Yajing and Li, Jiexiao and Ming, Jie},
title = {Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy},
journal = {Cells},
year = {2026},
volume = {15},
number = {15},
pages = {1422},
doi = {10.3390/cells15151422}
}
EUVIMED